Cite
SAT-389 HBV and HBsAg strongly reshape the phenotype, function and metabolism of DCs according to patients' clinical stage.
MLA
Dumolard, Lucile, et al. “SAT-389 HBV and HBsAg Strongly Reshape the Phenotype, Function and Metabolism of DCs According to Patients’ Clinical Stage.” Journal of Hepatology, vol. 80, June 2024, p. S744. EBSCOhost, https://doi.org/10.1016/S0168-8278(24)02091-9.
APA
Dumolard, L., Théophile, G., Chuffart, F., Decaens, T., Hilleret, M.-N., Larrat, S., Saas, P., Jouvin-Marche, E., Durantel, D., Marche, P. N., Jilkova, Z. M., & Aspord, C. (2024). SAT-389 HBV and HBsAg strongly reshape the phenotype, function and metabolism of DCs according to patients’ clinical stage. Journal of Hepatology, 80, S744. https://doi.org/10.1016/S0168-8278(24)02091-9
Chicago
Dumolard, Lucile, Gerster Théophile, Florent Chuffart, Thomas Decaens, Marie-Noëlle Hilleret, Sylvie Larrat, Philippe Saas, et al. 2024. “SAT-389 HBV and HBsAg Strongly Reshape the Phenotype, Function and Metabolism of DCs According to Patients’ Clinical Stage.” Journal of Hepatology 80 (June): S744. doi:10.1016/S0168-8278(24)02091-9.